Frontline Treatment Strategies in EGFR-Mutant NSCLC
Frontline Treatment Strategies in EGFR-Mutant NSCLC
December 2017
- A 73-year-old Caucasian man was seen in the emergency department for severe dyspnea and chest pain
- History: symptomatic COPD managed on fluticasone and vilanterol inhaler; 50-pack/year smoking history
- Imaging studies:
- Chest X-Ray showed a large mass in the lung right upper lobe
- CT of chest, abdomen, and pelvis revealed a 6.8-cm mass right-sided mass invading the chest wall, small left pleural effusion, and several small lytic lesions in the T4/5 vertebrae
- CT-guided transthoracic needle biopsy of the lung lesion showed grade 2 adenocarcinoma
- Molecular testing, NGS: EGFR exon 21 L858R mutation
- Staging: T3N0M1
- ECOG 1
- The patient was started on osimertinib 80 mg once daily
Related Videos
Related Content
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Article
Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
